Assessment of diffuse Lewy body disease by 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2385
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Assessment of diffuse Lewy body disease by 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) ; volume:3 ; number:1 ; day:20 ; month:2 ; year:2003 ; pages:1-4 ; date:12.2003
BMC nuclear medicine ; 3, Heft 1 (20.2.2003), 1-4, 12.2003
- Creator
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/1471-2385-3-1
- URN
-
urn:nbn:de:101:1-2019080722292209766722
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mirzaei, Siroos
- Knoll, Peter
- Koehn, Horst
- Bruecke, Thomas
- SpringerLink (Online service)
Other Objects (12)
Appearance of adrenal myelolipomas on 2-deoxy-2-(18F) fluoro-D-glucose positron emission tomography-computed tomography
Test-Retest Stability of Cerebral 2-Deoxy-2-[18F]Fluoro-D-Glucose ([18F]FDG) Positron Emission Tomography (PET) in Male and Female Rats
Positron emission tomography agent 2-deoxy-2-[18F]fluoro-D-glucose has a therapeutic potential in breast cancer
Using 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) to study carbon allocation in plants after herbivore attack
Role of brain 2-[18F]fluoro-2-deoxy-D-glucose-positron-emission tomography as survival predictor in amyotrophic lateral sclerosis
Spatial relationship of 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography and magnetic resonance diffusion imaging metrics in cervical cancer
Optimal 2-[18F]fluoro-2-deoxy-d-galactose PET/CT protocol for detection of hepatocellular carcinoma
Monitoring Response to Radiotherapy in Human Squamous Cell Cancer Bearing Nude Mice: Comparison of 2′-deoxy-2′-[18F]fluoro-d-glucose (FDG) and 3′-[18F]fluoro-3′-deoxythymidine (FLT)
![Wertigkeit der Positronen-Emissions-Tomographie mit 2-[18F]-Fluoro-2-Deoxy-D-Glukose in der Rezidivdiagnostik des Ovarialkarzinoms](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
Wertigkeit der Positronen-Emissions-Tomographie mit 2-[18F]-Fluoro-2-Deoxy-D-Glukose in der Rezidivdiagnostik des Ovarialkarzinoms
Dissociation between 2-[18F]fluoro-2-deoxy-D-glucose positron emission computed tomography, ultrasound and clinical assessments in patients with non-severe rheumatoid arthritis, including remission
Discovery of pre-therapy 2-deoxy-2-18F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients
Optimisation of Animal Handing and Timing of 2-deoxy-2-[18F]fluoro-D-glucose PET Tumour Imaging in Mice
Appearance of adrenal myelolipomas on 2-deoxy-2-(18F) fluoro-D-glucose positron emission tomography-computed tomography
Test-Retest Stability of Cerebral 2-Deoxy-2-[18F]Fluoro-D-Glucose ([18F]FDG) Positron Emission Tomography (PET) in Male and Female Rats
Positron emission tomography agent 2-deoxy-2-[18F]fluoro-D-glucose has a therapeutic potential in breast cancer
Using 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) to study carbon allocation in plants after herbivore attack
Role of brain 2-[18F]fluoro-2-deoxy-D-glucose-positron-emission tomography as survival predictor in amyotrophic lateral sclerosis
Spatial relationship of 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography and magnetic resonance diffusion imaging metrics in cervical cancer
Optimal 2-[18F]fluoro-2-deoxy-d-galactose PET/CT protocol for detection of hepatocellular carcinoma
Monitoring Response to Radiotherapy in Human Squamous Cell Cancer Bearing Nude Mice: Comparison of 2′-deoxy-2′-[18F]fluoro-d-glucose (FDG) and 3′-[18F]fluoro-3′-deoxythymidine (FLT)
Wertigkeit der Positronen-Emissions-Tomographie mit 2-[18F]-Fluoro-2-Deoxy-D-Glukose in der Rezidivdiagnostik des Ovarialkarzinoms
Dissociation between 2-[18F]fluoro-2-deoxy-D-glucose positron emission computed tomography, ultrasound and clinical assessments in patients with non-severe rheumatoid arthritis, including remission
Discovery of pre-therapy 2-deoxy-2-18F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients
Optimisation of Animal Handing and Timing of 2-deoxy-2-[18F]fluoro-D-glucose PET Tumour Imaging in Mice
Appearance of adrenal myelolipomas on 2-deoxy-2-(18F) fluoro-D-glucose positron emission tomography-computed tomography
Test-Retest Stability of Cerebral 2-Deoxy-2-[18F]Fluoro-D-Glucose ([18F]FDG) Positron Emission Tomography (PET) in Male and Female Rats
Positron emission tomography agent 2-deoxy-2-[18F]fluoro-D-glucose has a therapeutic potential in breast cancer
Using 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) to study carbon allocation in plants after herbivore attack
Role of brain 2-[18F]fluoro-2-deoxy-D-glucose-positron-emission tomography as survival predictor in amyotrophic lateral sclerosis
Spatial relationship of 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography and magnetic resonance diffusion imaging metrics in cervical cancer
Optimal 2-[18F]fluoro-2-deoxy-d-galactose PET/CT protocol for detection of hepatocellular carcinoma
Monitoring Response to Radiotherapy in Human Squamous Cell Cancer Bearing Nude Mice: Comparison of 2′-deoxy-2′-[18F]fluoro-d-glucose (FDG) and 3′-[18F]fluoro-3′-deoxythymidine (FLT)
Wertigkeit der Positronen-Emissions-Tomographie mit 2-[18F]-Fluoro-2-Deoxy-D-Glukose in der Rezidivdiagnostik des Ovarialkarzinoms
Dissociation between 2-[18F]fluoro-2-deoxy-D-glucose positron emission computed tomography, ultrasound and clinical assessments in patients with non-severe rheumatoid arthritis, including remission
Discovery of pre-therapy 2-deoxy-2-18F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients